Trials / Completed
CompletedNCT00467259
Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
A Randomized, Double-Blind, Placebo-controlled, Multicenter, 52-week Study to Evaluate the Endometrial Safety of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,271 (actual)
- Sponsor
- Warner Chilcott · Industry
- Sex
- Female
- Age
- 45 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the endometrial safety of a testosterone patch as treatment for low libido in naturally postmenopausal women.
Detailed description
Naturally postmenopausal women with hypoactive sexual desire disorder (HSDD) will be randomized into a 52-week, multicenter, double-blind (DB), parallel-group, placebo-controlled study. Patients will be stratified based on whether they use concomitant estrogen/progestin therapy and then randomized in a 4:1 ration to receive either testosterone transdermal system (300 mcg/day) or placebo. Patients using estrogen/progestin at the start of the study should maintain this therapy throughout the study; patients not using estrogen/progestin at the start of the study should not initiate estrogen/progestin therapy throughout the study. Endometrial biopsies and transvaginal ultrasounds will be collected/performed at screening and study exit for all patients. Safety will be assessed by adverse events, reports of vaginal bleeding, lipids, serum chemistry, and hematology. Physical exams, pap smears, and mammograms will be monitored.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Testosterone Transdermal System | Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks |
| DRUG | Placebo patch | placebo patch, changed twice a week for 52 weeks |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2007-04-30
- Last updated
- 2011-12-15
- Results posted
- 2011-12-15
Locations
115 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00467259. Inclusion in this directory is not an endorsement.